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A B S T R A C T
A 41-year-old gentleman with a recent history of Hodgkin’s lymphoma sustained an 
acute inferior wall myocardial infarction, managed with percutaneous coronary inter-
vention, thromboaspiration and stenting in a totally occluded right coronary artery. 
He was placed on triple antithrombotic treatment with dual antiplatelet therapy and 
oral anticoagulation because of a large thrombotic load in the right coronary artery. 
Three months later and 5 days after discontinuation of prescribed oral anticoagulant, 
he had a new acute coronary event due to acute reocclusion in the right coronary ar-
tery. Thrombus aspiration and repeat angioplasty restored vessel patency. The patient 
was put back on triple antithrombotic therapy and was investigated for uncommon 
causes of blood hypercoagulability. Blood assays revealed elevated anti-β2 glycopro-
tein I (anti-β2GPI) (IgM) and anticardiolipin antibodies (IgM), consistent with a di-
agnosis of secondary antiphospholipid syndrome.
I n T R o d u C T I o n
Coronary thrombosis as a manifestation of the antiphospholipid syndrome (APS) is 
rather uncommon. Patients with APS usually present with recurrent episodes of deep 
vein thrombosis, pulmonary thromboembolism or thromboembolic stroke. Recurrent 
coronary events have only been rarely reported. We describe a case of a 41-year-old 
patient with prior percutaneous coronary intervention (PCI) who had recurrent epi-
sode of acute coronary ischemia after discontinuation of oral anticoagulant agent and 
laboratory testing revealed anti-β2 glycoprotein I (anti-β2GPI) and anticardiolipin 
(aCL) antibodies.
C A S e  R e p o R T
A 41-year-old male patient with no history of coronary artery disease, habitual 
smoker without any other risk factor for coronary disease, presented to the emergency 
department complaining of crushing retrosternal chest pain which woke him up. The 
pain radiated down to his left arm and was accompanied by diaphoresis. The patient 
had been diagnosed with Hodgkin’s lymphoma one year earlier and he had already 
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completed 13 cycles of chemotherapy with ABVD (adriamycine, 
bleomycin, vinblastin and dacarbazine). He was also recently 
started on a new chemotherapeutic regimen with cemcitabine 
and vinorebline having already completed 2 cycles of it; last 
cycle was received 10 days prior to this admission.
At presentation, he was pale with a pulse of 70 beats/min 
and a blood pressure of 125/80 mmHg. Heart sounds were 
normal without any audible murmurs and lung auscultation was 
also normal. He had no peripheral edema and all peripheral 
pulses were present. The 12-lead surface electrocardiogram 
(ECG) showed ST-segment elevation in the inferior leads II, 
III, aVF (Fig. 1). Cardiac enzymes were found elevated with 
high sensitivity troponin T levels at 2150 pg/ml; other blood 
tests were within normal limits; the platelet count was >120000. 
Accordingly, a diagnosis of an acute inferior wall myocardial 
infarction (MI) was established and the patient was submit-
ted to primary percutaneous coronary intervention (PCI). 
Coronary angiography revealed total proximal occlusion of 
the right coronary artery (RCA) and presence of intracoronary 
thrombus (Fig. 2, panel A); the left coronary artery was pat-
ent. A thrombus aspiration catheter (Export®) was used and 
a large amount of thrombotic material was aspirated from the 
RCA (Fig. 2, panel C); four Genous® stents were subsequently 
implanted that restored vessel patency (Fig. 2, panel B). At 
the same time, intravenous eptifibatide (a platelet glycoprotein 
IIb/IIIa inhibitor) was started and administered for 24 hours. 
The patient was discharged home 4 days later with prescrip-
tions that included oral anticoagulation with acenocoumarol 
instructed to maintain a target INR between 2.0 and 2.5, low-
dose aspirin, clopidogrel, beta-blocker, nitrates and a statin.
The patient received 5 more cycles of chemotherapy in-
cluding cemcitabine and vinorebline without interrupting 
his triple antithrombotic regimen (dual antiplatelet therapy 
and anticoagulant agent). Three months later however, he 
FIguRe 1. 12-lead ECG during chest discomfort with ST-segment elevation in leads II, III, aVF and ST-segment depression in leads 
I, aVL.
FIguRe 2. Coronary angiogram showed complete occlusion of the proximal right coronary artery , filled with thrombus (A), which 
was fully recanalized after thrombus aspiration and stent implantation (B). The aspirated thrombotic material is displayed in panel C. 
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discontinued oral anticoagulation therapy for fear of develop-
ing severe pancytopenia as a result of intense chemotherapy 
(ESHAP scheme: etoposide, methylprednisolone, cytarabine, 
cisplatin) with a further plan to undergo autologous bone 
marrow transplantation.
Five days after the discontinuation of acenocoumarol, the 
patient presented to the emergency department again with a 
clinical and electrocardiographic picture of a new inferior wall 
MI. He was initially stabilized and 24 hours later he underwent 
coronary angiography which revealed reoccluded RCA (Fig. 
3, panel A). Thrombus aspiration (Fig. 3, panel C) was again 
performed using the Export® aspiration system followed by 
implantation of additional 3 stents which again restored vessel 
patency (Fig. 3, panel B). The patient received eptifibatide for 
24 hours and acenocoumarol was restarted.
Due to the recurrence of myocardial ischemia in a young 
patient along with the presence of a heavy thrombotic load 
within the affected coronary artery in the absence of other 
risk factors except for smoking, the patient underwent a full 
search for thrombophilia, which revealed abnormally elevated 
anti-β2 glycoprotein I (anti-β2GPI) IgM and aCL IgM (Table 
1). Based on these finding, the diagnosis of secondary APS was 
established and he was discharged on aspirin, clopidogrel, statin, 
nitrates, propranolol and acenocoumarol. Echocardiography 
indicated a mild decrease in left ventricular function. The 
patient remains asymptomatic one year later.
d I S C u S S I o n
The antiphospholipid syndrome (APS) is a systemic au-
toimmune disease characterized by the presence of persisting 
antiphospholipid antibodies (APA) along with a thrombotic 
event (arterial or venous thrombosis) and/or recurrent fetal 
loss due to placental thrombosis. The syndrome occurs in the 
absence (primary APS) or in association with another systemic 
autoimmune disease (secondary APS), mainly systemic lupus 
erythematosus.1,2 Approximately half the patients with APS have 
TABle 1. Thrombophilia Testing Results
Antibodies examined
Test Result Reference 
Anti cardiolipineIgG 4.5 0.1-20 GPL
Anti cardiolipineIgM 63.8* 0.1-20 MPL
Anti β2GPI-IgG 5.2 0.1-8 GPU
Anti β2GPI-IgM 22.7* 0.1-8 MPU
Molecular control (pCR) for mutation 
Factor Mutation gene Result
Factor V (Q 506) negative
Factor II (prothrombine) (G20210A) negative
Homocysteine (MTHFR) negative
* Abnormal results
anti-β2GPI = anti-β2 glycoprotein I antibodies; PCR = polymerase chain reaction. 
FIguRe 3. Total occlusion of the right coronary artery (A) and restoration of flow after percutaneous coronary intervention and 
thromboaspiration (B); aspirated thrombi shown in panel C.
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no underlying systemic autoimmune disease. Cardiovascular 
manifestations are observed in approximately 12% of APS 
patients including thrombotic lesions on cardiac valves or 
coronary artery thrombosis resulting in myocardial ischemia.3 
Myocardial infarction is diagnosed in 5.5% of patients with APS 
and is the presenting manifestation in 2.8% of APS patients.4 
In a study of MI patients under the age of 45 years, 21% had 
persisting APA meeting diagnostic criteria for APS.5
Among all malignancies, lymphoma is the fourth malignant 
tumor most likely to be associated with significant morbidity 
and mortality related to thrombosis. Pusterla et al6 supported 
that APA positive patients suffering from different lymphomas 
are at high risk for thrombotic complications. Zuckerman et al7 
reported an increased incidence of vascular thrombosis (22%) 
among APA positive cancer patients. A tendency for thrombo-
embolism to occur in APA positive non-Hodgkin lymphomas 
was correlated with thrombocytopenia at presentation and poor 
platelet recovery following chemotherapy.8 Among 86 patients 
with non-Hodgkin lymphoma, Bairey et al reported that 41% 
were found with elevated APA levels and such a finding was 
correlated with shortened survival and has been proposed as 
an independent prognostic variable.9
Antiphospholipid antibodies were first suggested to be in-
volved in atherosclerosis in 1993.10 Antiphospholipid antibodies 
constitute a heterogenous group of antibodies directed against 
phospholipid–binding proteins. Current laboratory criteria for 
APS require two positive tests of anticardiolipin antibodies 
(aCL), lupus anticoagulant and/or anti-β2-GPI antibodies at 
least 12 weeks apart. APA are not only diagnostic but also 
pathogenic auto-antibodies; different mechanisms have been 
proposed according to which APA cause thrombosis in normal 
vessels, are associated with accelerated atherosclerosis or even 
arise at the time of MI as a result to vascular injury and expo-
sure to neoantigens.11 APA exert direct proinflammatory and 
procoagulant activity on the endothelial surface and may also 
trigger the inflammatory cascade. Venous thrombotic events 
are more frequent in lupus anticoagulant positive patients 
while coronary/carotid/ peripheral arterial thromboses are 
more frequent in patients with elevated serum levels of aCL 
or anti-β2-GPI antibodies.12
Several studies suggest the involvement of APA in cardio-
vascular events; APA is positively associated with the presence 
of coronary disease and increased risk of ischemic stroke or MI. 
According to a study on patients with cardiovascular disease, 
fewer than 2.6% of patients were positive for aCL, whereas 
35.6 % were IgA and 1.6% were IgG positive for anti-β2-GPI 
antibodies13 which have been found to increase coagulation 
via the plasminogen pathway and by enhancing platelet adhe-
siveness. In a prospective study of 415 patients, Neville et al14 
found that APA predict vascular events independently from 
other risk factors; apart from prior vascular event, diabetes, 
gender, age, or activated protein C resistance, it was found 
that APA positivity predicts imminent arterial or vascular 
events. Women aged <50 years with a myocardial infarction 
or an ischemic stroke were enrolled in the RATIO study.15 
Different APA and genetic prothrombotic risk factors were 
measured and it was demonstrated that the lupus anticoagu-
lant is a major independent risk factor for arterial thrombotic 
events in young women.15 Meroni et al16 also found that IgG/
IgM anti-β2-GPI antibodies is a significant risk factor for MI 
in premenopausal women independently of other risk factors 
(e.g. degree of coronary artery stenosis) while the significance 
of IgG aCL is minor. The hypothesis that aCL participate in 
the pathogenesis of MI has also been reported, due to their 
inflammatory and procoagulant properties. Zuckerman et al17 
suggested that high levels of aCL are risk factor for subsequent 
thromboembolic events or myocardial reinfarction after acute 
MI in relatively young survivors of acute MI. Moreover, in a 
recent study by Sacre et al,18 an unexpectedly high prevalence 
of occult myocardial ischemic disease in APS patients was 
detected by cardiac magnetic resonance imaging; yet the 
number of patients was small and further studies are needed 
to clarify such a finding.
It has also been reported that APA are associated with 
adverse events and outcomes in angioplasties and coronary 
artery bypass, especially in young patients.19 Greco et al20 
found that the presence of APA are not only associated with 
the presence of coronary disease but also with an increase 
in adverse cardiac outcomes of patients undergoing proce-
dures (angioplasty, stent, bypass) (P=0.045) and extracardiac 
thrombotic events (P=0.033). At present, only levels of aCL 
(not levels of anti-β2-GPI) antibodies are proposed as inde-
pendent risk factors for recurrent cardiac events regarding 
postinfarction patients; in fact, patients with elevated levels of 
IgG aCL and low levels of IgM aCL antibodies have a 3-fold 
higher risk for recurrent cardiac events.21 Patients with APS 
undergoing PCI have worse long-term clinical outcomes and 
higher levels of revascularization, caused by both restenosis 
within the stent(s) and accelerated atherosclerosis in vessel 
areas not covered by stents.22 Although drug eluting stents 
are a major breakthrough in the struggle against restenosis, 
contraindications due to coagulation abnormalities may arise 
in APS patients and should be taken into account in order to 
avoid stent thrombosis. To limit potentially life-threatening 
thrombotic complications by angioplasty procedures which 
routinely cause vascular damage, prolonged dual antiplatelet 
therapy combined with anticoagulant treatment should be 
considered, while thrombophilia screening should be included 
in the diagnostic workup.3
APS should be considered as a potential cause of acute 
coronary syndrome in younger patients (<55 in men and <65 
in women) with structurally normal coronary arteries, no other 
traditional cardiovascular risk factors, no history of drug abuse 
or congenital abnormality, who have a history of recurrent 
thrombotic events and/or abnormal coagulation test results. 
There is lack of prospective randomized placebo-controlled 
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trials evaluating specific diagnostic and therapeutic approaches 
in APS patients with an acute coronary syndrome. Nevertheless 
there is consensus that APS patients should receive life-long 
anticoagulation therapy for secondary thromboprophylaxis; 
patients with prior venous thrombosis should have a target INR 
of 2.0-3.0 and patients with arterial thrombosis a target INR 
of >3.0.2,23 Retrospective and prospective studies have shown 
the efficacy of warfarin for secondary thrombosis prevention 
in APS.24 Based on retrospective studies, 20–70% of patients 
with APS develop recurrent thrombosis when they stop antico-
agulation treatment. Statins have also been proposed in APS 
drug therapy due to their antithrombotic, anti-inflammatory 
and pleiotropic effects on vascular endothelium. It remains 
unknown whether novel orally administered agents, including 
dabigatran etexilate (direct thrombin inhibitor) and rivaroxaban 
or apixaban (direct factor Xa inhibitors), have any therapeutic 
potential in APS patients. Further trials are needed to deter-
mine the advantages and risks of these agents.25
C o n C l u S I o n
The antiphospholipid syndrome (APS), though uncom-
mon, is an acquired autoimmune hypercoagulable state which 
should be considered when investigating young patients who 
have experienced an acute coronary syndrome without other 
predisposing factors for coronary disease. APS patients with a 
coronary syndrome and coronary angioplasty have an increased 
risk for recurrent cardiac event and should receive life-long 
anticoagulation therapy apart from anti-ischemic and anti-
thrombotic treatment.
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